Computer-Aided Lead Optimization: Improved Small-Molecule Inhibitor of the Zinc Endopeptidase of Botulinum Neurotoxin Serotype A by Tang, Jing et al.
Computer-Aided Lead Optimization: Improved Small-
Molecule Inhibitor of the Zinc Endopeptidase of
Botulinum Neurotoxin Serotype A
Jing Tang
1, Jewn Giew Park
1, Charles B. Millard
2, James J. Schmidt
3*, Yuan-Ping Pang
1*
1Computer-Aided Molecular Design Laboratory, Mayo Clinic, Rochester, Minnesota, United States of America, 2Division of Biochemistry, Walter Reed
Army Institute of Research, Silver Spring, Maryland, United States of America, 3Department of Cell Biology and Biochemistry, United States Army
Medical Research Institute of Infectious Diseases, Frederick, Maryland, United States of America
Optimization of a serotype-selective, small-molecule inhibitor of botulinum neurotoxin serotype A (BoNTA) endopeptidase is
a formidable challenge because the enzyme-substrate interface is unusually large and the endopeptidase itself is a large, zinc-
binding protein with a complex fold that is difficult to simulate computationally. We conducted multiple molecular dynamics
simulations of the endopeptidase in complex with a previously described inhibitor (Ki
app of 762.4 mM) using the cationic
dummy atom approach. Based on our computational results, we hypothesized that introducing a hydroxyl group to the
inhibitor could improve its potency. Synthesis and testing of the hydroxyl-containing analog as a BoNTA endopeptidase
inhibitor showed a twofold improvement in inhibitory potency (Ki
app of 3.860.8 mM) with a relatively small increase in
molecular weight (16 Da). The results offer an improved template for further optimization of BoNTA endopeptidase inhibitors
and demonstrate the effectiveness of the cationic dummy atom approach in the design and optimization of zinc protease
inhibitors.
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INTRODUCTION
Botulinum neurotoxin serotype A (BoNTA) is a protein produced
by the spore-forming anaerobic bacterium, Clostridium botulinum.
The neurotoxin consists of a light chain (Mr ,50,000) and a heavy
chain (Mr,100,000) linked covalently by a disulfide bond.
BoNTA poisoning selectively inhibits the release of acetylcholine
from presynaptic nerve terminals at neuromuscular junctions, thus
causing flaccid paralysis and leading to prolonged mechanical
ventilation with serious medical sequelae or death following
respiratory arrest [1]. In small doses BoNTA is an effective
medical treatment for a variety of cholinergic nerve and muscle
dysfunctions [2,3]. In addition to its medical applications, BoNTA
has gained notoriety as a bioterror agent [4]. Because there is no
antidote to BoNTA, effective small-molecule inhibitors of BoNTA
are highly sought after as antidotes and as potential medical tools
for modulating clinical uses of the toxin.
The light-chain domain of BoNTA is a zinc endopeptidase that
specifically cleaves SNAP-25, a neuronal protein required for
acetylcholine release [5]. The endopeptidase has been used as
a target for developing small-molecule inhibitors of BoNTA [6–
15]. Recently, we reported the development of a serotype-
selective, small-molecule inhibitor of BoNTA with a Ki of
1262.6 mM( 1, Figure 1) [7]. Developing or optimizing small-
molecule inhibitors of BoNTA endopeptidase is, however, as
challenging as developing small-molecule inhibitors of protein-
protein complexes, a challenge that has been known for decades
[16]. The challenge in the case of BoNTA endopeptidase
inhibitors can be partly attributed to the substrate that wraps
around the circumference of BoNTA endopeptidase upon binding
and creates a substrate-enzyme interface of 4840 A ˚ 2 [17]. This large
interface requires a high-affinity small molecule to block it. The
extent of this challenge can be appreciated by comparing the
interface area of BoNTA endopeptidase (4840 A ˚ 2) to the typical
protein-protein interface area of 750–1500 A ˚ 2 [16]. Another part of
the challenge in developing and optimizing these inhibitors is the
endopeptidase itself, which is a large zinc-binding protein with
a complex fold that is capable of large-scale conformational changes
in solution and that is therefore difficult to simulate computationally
[17]. Consequently, computer-aided optimization of BoNTA
endopeptidase inhibitor leads has not been reported until now.
We report computer-aided optimization of 1 to arrive at an
improved, serotype-selective, small-molecule BoNTA endopeptidase
inhibitor with an ‘‘apparent’’ Ki (Ki
app)o f3 . 8 60.8 mM. This
optimization was guided by multiple molecular dynamics simula-
tions (MMDSs) of the zinc-containing endopeptidase in complex
with 1 using the cationic dummy atom (CaDA) approach. This
approach introduces four identical dummy atoms in a tetrahedral
geometry around the zinc ion and transfers all the atomic charge of
the zinc divalent cation evenly to the dummy atoms. The four
peripheral atoms are ‘‘dummy’’ in that they interact with other
atoms electrostatically but not sterically, thus mimicking the 4s4p
3
vacant orbitals of the zinc divalent cation that accommodate the
lone-pair electrons of zinc coordinates [18–23]. The results offer an
improved template for further optimization of BoNTA endopepti-
dase inhibitors and demonstrate that the CaDA approach is useful
for both design and optimization of zinc protease inhibitors.
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Design
Inhibitor 1 was designed to coordinate the zinc divalent cation
embedded in the active site of BoNTA endopeptidase for affinity
and simultaneously to interact with serotype-specific residues in
the active site for selectivity [7]. This design was based on previous
MMDSs using the CaDA approach. The MMDSs (20 simulations)
of the endopeptidase in complex with 1 showed that (1) the
hydroxamate group coordinated the active-site zinc ion; (2) the
phenyl group substituted at the thiophene ring had a p-p
interaction with Phe193 and a cation-p interaction with Arg362;
(3) the indole ring was engaged in a cation-p interaction with
Lys165; (4) the phenyl group attached to the indole ring had a van
der Waals interaction with the side chain of Leu527 and a cation-p
interaction with Lys165; (5) the ammonium group interacted with
the carboxylates of Glu54 and Glu55 [7]. The absolute free energy
binding between 1 and the endopeptidase was estimated to be
27.5 kcal/mol according to a free energy perturbation calculation
of the MMDS-derived model of the 1-bound endopeptidase using
a published method [24] with modifications described in
MATERIALS AND METHODS. These computational observa-
tions were consistent with the experimentally determined Ki
app of
762.4 mM( DG ranging from –6.9 to –7.3 kcal/mol) for 1 (see
below). In this context, the MMDS-derived model of the 1-bound
endopeptidase was used for the following lead optimization.
An analysis of the MMDS trajectories of the endopeptidase in
complex with 1 identified a vacancy around the meta position of
the phenyl group substituted on the thiophene of 1. Synthetically,
this void can be filled by a hydroxyl group substituted at the
phenyl ring. This hydroxyl group can form hydrogen bonds with
active-side residues to improve the affinity for the endopeptidase
and the introduction of this hydroxyl group can also increase the
hydrophilicity of 1 because dimethyl sulfoxide is needed to dissolve
1 in water. These considerations led to the design of inhibitor 2
(Figure 1). MMDSs (20 simulations) of the endopeptidase incomplex
with 2 were carried out to confirm the anticipated hydrogen bonds.
The result of these simulations suggested that 2 binds at the active
site of BoNTA endopeptidase in a manner similar to that of 1 and
thatthe hydroxyl group attachedto thephenylgroup of2 indeedhas
hydrogen bonds with Arg362 and Asp369 of the endopeptidase
(Figure 2). In the average structure of the endopeptidase complex
obtained from 10,000 instantaneous structures at 1.0-ps intervals
during the last 0.5-ns period of the 20 different simulations using an
explicit water model [25], the hydrogen bond of 2 to Arg362 is
bridgedbyawatermolecule;theaveragedistancesfromthephenolic
oxygen atom to the carboxylate oxygen atom of Asp369 and the
water oxygen atom are 2.9 A ˚ and 2.3 A ˚, respectively; the average
distance between the water oxygen atom and the closest guanidi-
nium nitrogen atom of Arg362 is 3.3 A ˚.
Synthesis
The initial synthesis of 2 followed a published scheme [7] that was
devised to synthesize 1. The starting material methyl 2-(2-(3-
hydroxyphenyl)thiophen-3-yl)acetate (4) was prepared using Su-
zuki coupling [26–28] (Figure 3). However, the yield of Friedel-
Crafts acylation [29,30] for preparing 5 (Figure 3) was reduced to
Figure 1. Chemical structures of inhibitors 1 and 2.
doi:10.1371/journal.pone.0000761.g001
Figure 2. A close-up view of inhibitor 2 binding at the active site of the botulinum neurotoxin serotype A endopeptidase. The 3D model was
generated by averaging 10,000 instantaneous structures obtained at 1.0-ps intervals during the last 0.5-ns period of 20 molecular dynamics
simulations (2.0 ns for each simulation with a 1.0-fs time step and a unique seed for initial velocities) followed by 200 steps of energy minimization of
the average structure of the entire complex.
doi:10.1371/journal.pone.0000761.g002
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phenyl ring. To increase the yield, a new scheme was devised to
perform Friedel-Crafts acylation first and then Suzuki coupling
(Figure 4); this scheme enables facile derivatization of the phenyl
group substituted at the thiophene ring via a traditional or
combinatorial chemistry approach. As shown in Figure 4, Heck
alkynylation [31] of 7, which carries both bromo and iodo atoms,
was selectively achieved to afford 8 by using PhCCH/
Pd(PPh3)2Cl2,K 2CO3, and Et3N in DMF. A catalytic amount of
InBr3 [32] was used for the indole formation to obtain 9 in a high
yield. To obtain 10, N-alkylation of the indole ring was carried out
under the same conditions reported for the synthesis of 1 [7].
Refluxing 10 with 3-hydroxyphenylboronic acid in toluene:etha-
nol containing PdCl2(PPh3)2 and Na2CO3 gave 11 in a higher
yield than a known procedure [33]. The final product 2 was
obtained by a reaction of 11 with excess hydroxylamine [34] that
simultaneously converted methyl ester and phthalimide to
hydroxamic acid and amine, respectively [35,36]. High-perfor-
mance liquid chromatography (HPLC) purification using solvent
containing trifluoroacetic acid yielded pure 2 in its trifluoroacetic
acid salt form that was used for the following testing.
Testing
HPLC-based kinetics assays [37] were used to measure the
inhibition of BoNTA endopeptidase and a related endopeptidase
from botulinum neurotoxin serotype B by 1 and 2.AKi value of
1262.6 mM was previously obtained for 1 that was assumed to be
a competitive inhibitor [7]. A further investigation on inhibitor
effectiveness in this study revealed nonlinear Dixon plots for both
1 and 2 with data obtained at the condition of [S],,KM
(Figure 5). The curvature of these plots indicates a partially
competitive inhibition mechanism for 1 and 2 [38]; it precludes
determination of Ki values using standard kinetic methods and
invalidates the previously reported Ki value for 1. To compare the
relative inhibitory potencies of the two inhibitors, Ki
app values of 1
and 2 were therefore obtained from the slope of 1/n versus [I] at
the conditions of [S],,KM and inhibitor concentrations less than
15.0 mM and 5.4 mM, respectively, according to a literature
procedure [38,39]. The Dixon plots for 1 and 2 are approximately
linear at relatively low concentrations (Figure 5). Consequently,
the kinetics assays showed that (1) at low inhibitor concentrations,
1 and 2 are competitive inhibitors of BoNTA endopeptidase with
Ki
app values of 762.4 mM and 3.860.8 mM, respectively, in
HEPES buffer at pH 7.3, consistent with the half maximal
inhibitory concentrations independently determined for the
inhibition of BoNTA endopeptidase by 1 (1561.5 mM) and 2
(7.960.8 mM); (2) the Ki
app values of 1 and 2 were unaffected after
the zinc concentration of the assay was increased from 25 mMt o
50 mM while holding all other experimental variables constant; (3)
1 and 2 did not inhibit botulinum neurotoxin serotype B
endopeptidase at concentrations up to 20 mM (data not shown).
These results preclude the possibility that the inhibition of BoNTA
Figure 3. Synthetic scheme for intermediate 5.
doi:10.1371/journal.pone.0000761.g003
Figure 4. Synthetic scheme for inhibitor 2.
doi:10.1371/journal.pone.0000761.g004
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the observations demonstrate that 2 is a more potent BoNTA
endopeptidase inhibitor than 1.
DISCUSSION
Improved Inhibitor of BoNTA Endopeptidase
Our results show that 1 and 2 are competitive inhibitors of BoNTA
endopeptidase at inhibitor concentrations less than 15.0 mMa n d
5.4 mM, respectively, and that the Ki
app values of 1 and 2 are
762.4 mMa n d3 . 8 60.8 mM, respectively. However, both inhibitors
are partially competitive inhibitors at relatively high inhibitor
concentrations. These observations are not unprecedented. It has
been reported that a Dixon plot of a dipeptide inhibitor (Gly-Trp) of
angiotensin converting enzyme showed a competitive inhibition
mechanism at relatively low inhibitor concentrations and a complex
inhibition mechanism at relatively high concentrations, whereas the
same inhibitor showed a competitive inhibition mechanism in
a Lineweaver-Burk plot [39]. Interestingly, both BoNTA endopep-
tidase and angiotensin converting enzyme are zinc-bound enzymes.
Further studies are needed to investigate the detailed inhibition
mechanisms of 1 and 2 at relatively high concentrations. Neverthe-
less, the results of this study show clearly that 2 is a more potent
BoNTA endopeptidase inhibitor than 1, as evident from the Dixon
plots shown in Figure 5 and from the half maximal inhibitory
concentrations determined for the inhibition of BoNTA endopep-
tidase by 1 (1561.5 mM) and 2 (7.960.8 mM).
Efficiency of computer-aided optimization
While the optimization of 1 reported here was guided by MMDSs
using the CaDA approach, 12 other analogs of 1 were made
according to the scheme shown in Figure 4 using commercially
available phenylboronic acids without the MMDSs guidance.
Interestingly, none of these brute-force-approach-based derivatives
was found to be more potent than 2 (data not shown). In terms of
lead optimization for in vitro potency, which is an important step in
drug development, the present work offers another demonstration
of the relative efficiency of using computer simulations instead of
the brute force approach for lead optimization. The results suggest
that the CaDA approach is useful for both design and optimization
of zinc protease inhibitors.
Figure 5. Dixon plots for inhibition of the botulinum neurotoxin serotype A endopeptidase by inhibitors 1 (upper panels) and 2 (lower panels).
The right panels are the scale-up of the left panels.
doi:10.1371/journal.pone.0000761.g005
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As described above, the interface between BoNTA endopeptidase
and its substrate is more than twice as large as typical protein-
protein interfaces [16,17]. This large interface causes a conflict in
the design and optimization of medically useful BoNTA endo-
peptidase inhibitors in that, on the one hand, a large molecule is
needed to gain more interactions at the unusually large interface,
and on the other hand, a small molecule is required to ensure good
cell permeability. To avoid the conflict, optimization should be
directed towards improving inhibitor affinity with a small increase
in molecular weight. This strategy is necessary in early stages of
optimization of a micromolar lead because a bivalence or
fragment-based approach will be used in later stages of the
optimization to take advantage of peripheral sites or exosites on
the endopeptidase to achieve high affinity [12,13,17,40,41]. The
bivalence or fragment-based approach will be inapplicable to the
optimization if the molecular weight of a lead is already too
high. At present, the molecular weights of 1 and 2 are 524 and
540 Da, respectively. This study shows that it is practical to
achieve a twofold improvement in inhibitory potency with
a molecular weight increase of only 16 Da by adding one oxygen
atom, given the guidance of the MMDSs of BoNTA endopepti-
dase using the CaDA approach. Further optimization of 2
following the example reported herein is underway and will be
reported in due course.
MATERIALS AND METHODS
Computational Methods
Preparation of the zinc- and inhibitor-bound endopepti-
dase The initial structure of the zinc-containing BoNTA
endopeptidase was taken from an available crystal structure of
a BoNTA endopeptidase mutant (Glu224Gln and Tyr366Phe;
Protein Data Bank code: 1XTG, residue numbers of 1XTG
described in this section deviate by one from the residue numbers
described in RESULTS and in Figure 2) [17]. To change the
mutant back to the wildtype, residues 224 and 366 were mutated
to Glu and Tyr, respectively, and the dihedral N-CA-CB-CG of
Tyr366 was changed from 65.66 to –171.84u of arc. Hydrogen
atoms of the endopeptidase were added by using the QUANTA97
program (Accelrys Software, Inc, San Diego, California). The zinc
divalent cation in the crystal structure was replaced by the
tetrahedron-shaped zinc divalent cation that has four cationic
dummy atoms surrounding the central zinc ion [19] (for more
information on zinc protein simulations see ‘‘http://
mayoresearch.mayo.edu/mayo/research/camdl/zinc_protein.
cfm’’). His223, His227, and Glu262, which are the first-shell zinc
coordinates, were treated as histidinate (HIN) and glutamate
(GLU), respectively [19,20,42–44]. Glu261 and Glu351, which
form a hydrogen bond with His223 and His227 respectively, were
treated as glutamic acid (GLH) [19,20,42–44]. His170 and His269
were treated as the histidine whose epsilon nitrogen atom is
protonated (HIE); His39 and His230 were treated as the histidine
whose delta nitrogen atom is protonated (HID) and histidinium
(HIP), respectively. Inhibitor 1 or 2 was manually docked into the
active site of the endopeptidase according to a previously reported
3D model of inhibitor 1-bound BoNTA endopeptidase [7]. One
chloride ion was added next to the ammonium group of Lys381
located on the surface of the protein to neutralize the protein. The
published force field parameters of the tetrahedron-shaped zinc
divalent cation [7] were used in energy minimizations and in the
following described molecular dynamics simulations. The RESP
charges and the AMBER force field parameters of inhibitors 1 and
2 were generated by using the ANTECHAMBER module of the
AMBER 7 program [45] and the structures of 1 and 2 that were
optimized at the HF/6-31G* level with the Gaussian 98 Program
[46] (Figure S1 and Tables S1 and S2). A 10,000-step energy
minimization was first performed on inhibitor 2 with a positional
constraint applied to the rest of the complex. A 50-step energy
minimization was then performed on the tetrahedron-shaped zinc
divalent cation and 2 with a positional constraint applied to the
endopeptidase only. A 200-step energy minimization was lastly
performed on the entire complex without any constraint.
Multiple molecular dynamics simulations All MMDSs
(2.0 ns for each simulation with a unique seed number for starting
velocities of the system) were performed according to a published
protocol [47] using the PMEMD module of the AMBER 8
program [45] with the Cornell et al. force field (parm99.dat) [48].
The topology and coordinate files used for the MMDSs were
generated by the PREP, LINK, EDIT, and PARM modules of the
AMBER 5 program [45]. All simulations used (1) a dielectric
constant of 1.0; (2) the Berendsen coupling algorithm [49]; (3)
a periodic boundary condition at a constant temperature of 300 K
and a constant pressure of 1 atm with isotropic molecule-based
scaling; (4) the Particle Mesh Ewald method to calculate long-
range electrostatic interactions [50]; (5) iwrap=1; (6) a time step of
1.0 fs; (7) the SHAKE-bond-length constraints applied to all the
bonds involving the H atom; (8) default values of all other inputs of
the PMEMD module. The initial structure of the 2-bound BoNTA
endopeptidase used for the MMDSs had no structural water
molecules, and was solvated with TIP3P water molecules [25]
(EDIT input: NCUBE=10, QH=0.4170, DISO=2.20,
DISH=2.00, CUTX=8.0, CUTY=8.0, and CUTZ=8.0).
The solvated endopeptidase complex system was first energy-
minimized for 200 steps to remove close van der Waals contacts in
the solvated system, slowly heated to 300 K (10 K/ps), and then
equilibrated for 1.5 ns. The CARNAL module was used for
geometric analysis and for obtaining the time-average structure.
All MMDSs were performed on 40 Apple G5 processors. The
energy minimization of the time-average structure used
‘‘NCYC=50’’ and other default inputs of the SANDER module
of AMBER 5 [45], respectively.
Free energy perturbation calculation [24] The absolute
free energy of binding between 1 and BoNTA endopeptidase was
obtained by perturbing 1 to nothing over 24 windows of
perturbation using the thermodynamics integration method
implemented in the SANDER module of AMBER 8 [45]. Each
window was equilibrated and sampled with MMDSs (10
simulations) using the procedure described above. Each of the
MMDSs used a 1.0-fs time step and lasted 0.5 ns and 1.0 ns for
equilibration and sampling, respectively. The perturbation used
12/24-point Gaussian quadrature and the mixing rule shown in
Equation 1. This exceptionally computing intensive calculation
was performed on 480 Apple G5 processors for two months.
V(l) ~ (1 { l)





13C NMR spectra were recorded on
a Varian Mercury 400 spectrometer. Chemical shifts are reported
in ppm using the solvent resonance as the internal standard. Data
are reported as follows: chemical shift, multiplicity (s=single,
d=doublet, t=triplet, q=quartet, br=broad, and m=multiplet),
integration, and coupling constants. High-resolution mass spectra
were obtained on a Bruker BioTOF II ESI. THF and CH2Cl2
were dried using activated alumina columns from Solv-Tek
(Berryville, VA). DMF and CH3CN were dried by distillation
Lead Optimization
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were used as received. Medium-pressure liquid chromatography
(MPLC) was performed with Biotage SP-1 (Charlottesville, VA)
using silica gel 60 (EM Science, 230-400 mesh).
Methyl 2-(2-bromo-5-(4-iodo-3-nitrobenzoyl)thiophen-3-
yl)acetate (7) To a stirred solution of 2-(thiophen-3-yl)acetic
acid (6, 28.00 g, 196.94 mmol) in methanol (300 mL) was added
12 N HCl (15 mL) and then refluxed for two hours. Methanol was
removed by evaporation in vacuo, the residue was dissolved in
dichloromethane, washed with saturated NaHCO3 solution, dried
over MgSO4, filtered, and concentrated. Kugelrohr distillation of
the crude product at 90uC per 0.1 mmHg gave the desired ester as
a colorless oil (28.43 g, 92%).
1H NMR (400 MHz, CDCl3) d 3.67 (s, 2H), 3.71 (s, 3H), 7.04
(dd, 1H, J=1.2, 4.9 Hz), 7.20 (m, 1H), 7.29 (1H, dd, J=2.0,
4.9 Hz).
To a solution of the above ester (10.00 g, 64.02 mmol) in THF
(100 mL) was added NBS (11.40 g, 64.02 mmol). The resulting
mixture was refluxed for two and a half hours. The solvent was
removed in vacuo. MPLC purification (Hex:EtOAc/9:1) of the
residue gave (2-bromothiophen-3-yl)acetic acid as a colorless oil
(14.55 g, 97%).
1H NMR (400 MHz, CDCl3) d 3.64 (s, 2H), 3.72 (s, 3H), 6.93
(d, 1H, J=5.6 Hz), 7.25 (d, J=5.6 Hz).
To a stirred solution of methyl (2-bromothiophen-3-yl)acetate
(120 mg, 0.51 mmol) and 4-iodo-3-nitrobenzoyl chloride (150 mg,
0.48 mmol) in anhydrous CH2Cl2 (10 mL) was added AlCl3
(260 mg, 1.95 mmol) in four portions at 10-minute intervals at
room temperature. The resulting mixture was stirred overnight.
The reaction mixture was slowly poured onto 5 g of ice and
allowed to warm to room temperature. The aqueous phase was
extracted with CH2Cl2 (3615 mL). The combined organic layer
was dried over MgSO4, filtered, and then concentrated in vacuo.
MPLC purification (Hex:EtOAc/5:1) of the residue gave 7 as
a light yellow solid (158 mg, 61%).
1H NMR (400 MHz, CDCl3) d 8.27 (d, 1H, J=2.0 Hz), 8.22
(d, 1H, J=8.0 Hz), 7.70 (dd, 1H, J=2.0, 8.2 Hz), 7.48 (s, 1H),
3.74 (s, 3H) and 3.68 (s, 2H);
13C NMR (100 MHz, CDCl3)
d 183.8, 170.0, 153.2, 142.9, 141.9, 138.3, 136.5, 135.8, 133.1,
125.7, 124.5, 91.8, 52.6 and 35.0; HRMS-ESI calcd C14H9BrI-
NO5S[ M +Na] 531.8322, found 531.8331.
Methyl 2-(2-bromo-5-(3-nitro-4-(phenylethynyl)benzoyl)-
thiophen-3-yl)acetate (8) A solution of 7 (150 mg,
0.29 mmol), phenylacetylene (32 mL, 0.29 mmol), Pd(PPh3)2Cl2
(21 mg, 0.03 mmol), K2CO3 (42 mg, 0.29 mmol), and Et3N
(40 mL, 0.29 mmol) in DMF (3 mL) was stirred for 24 hours at
room temperature. Water (5 mL) was added to the mixture and
then extracted with EtOAc (3610 mL). The combined organic
layer was washed with brine, dried over MgSO4, and concentrated
in vacuo. MPLC purification (Hex:EtOAc/5:1) of the residue gave
8 as a solid foam (101 mg, 71 %).
1H NMR (400 MHz, CDCl3) d 8.54 (d, 1H, J=1.6 Hz,); 8.06
(dd, 1H, J=1.6, 8.0 Hz), 7.86 (d, 1H, J=8.4 Hz), 7.64 (m, 2H),
7.52 (s, 1H), 7.42 (m, 3H), 3.75 (s, 3H) and 3.70 (s, 2H);
13C NMR
(100 MHz, CDCl3) d 183.9, 170.1, 149.5, 142.2, 137.0, 136.3,
135.7, 135.3, 132.9, 132.5, 130.1, 128.8, 125.6, 124.3, 122.8,
122.1, 101.1, 84.7, 52.7 and 35.0; HRMS-ESI calcd
C22H14BrNO5S[ M +Na] 505.9668, found 505.9666.
Methyl (2-bromo-5-(2-phenyl-1H-indole-6-carbonyl)thio-
phen-3-yl)acetate (9) To a solution of 8 (25 mg, 0.05 mmol)
in EtOAc (5 mL) was added stannous chloride dihydrate (58 mg,
0.26 mmol). The resulting mixture was refluxed for one hour
under N2. The reaction mixture was poured onto ice (5 g), and
basified with saturated NaHCO3 solution to pH 8. The white
milky mixture was filtered through a Celite pad to remove tin
oxides. The organic layer from the filtrate was dried over MgSO4,
filtered, and then concentrated in vacuo. MPLC purification
(Hex:EtOAc/4:1) of the crude product gave the desired inter-
mediate methyl (2-bromo-5-(3-amino-4-(phenylethynyl)benzoyl)-
thiophen-3-yl)acetate as a yellow foam (21 mg, 90%).
1H NMR (400 MHz, CDCl3) d 7.55 (m, 2H), 7.50 (s, 1H), 7.48
(d, 1H, J=1.6 Hz), 7.38 (m, 3H), 7.17 (m, 2H), 4.40 (br, 2H), 3.73
(s, 3H) and 3.66 (s, 2H);
13C NMR (100 MHz, CDCl3) d 186.7,
170.3, 148.1, 143.4, 138.1, 135.9, 135.1, 132.4, 131.8, 129.0,
128.7, 122.9, 122.8, 118.8, 114.5, 112.3, 97.6, 85.3, 52.6 and 35.0;
HRMS-ESI calcd C22H16BrNO3S[ M +Na] 475.9926, found
475.9923.
To a 250 mL flask containing freshly distilled toluene (50 mL)
were added methyl (2-bromo-5-(3-amino-4-(phenylethynyl)ben-
zoyl)thiophen-3-yl)acetate (2.93 g, 6.45 mmol) and indium tribro-
mide (1.14 g, 3.22 mmol) under N2. The resulting mixture was
refluxed for one hour. The solvent was removed in vacuo. MPLC
purification (Hex:EtOAc/4:1) of the crude product gave 9 as
a yellow solid (2.50 g, 85%).
1H NMR (400 MHz, CDCl3) d 9.38 (br, 1H), 7.98 (s, 1H), 7.69
(d, 2H, J=7.8 Hz), 7.58 (m, 2H), 7.47 (s, 1H), 7.40 (t, 2H,
J=7.5 Hz), 7.30 (m, 1 H), 6.80 (s, 1H), 3.65 (s, 3H) and 3.59 (s,
2H);
13C NMR (100 MHz, CDCl3) d 187.4, 170.5, 144.2, 142.3,
136.5, 135.7, 134.9, 133.3, 131.8, 130.9, 129.4, 128.8, 125.9,
121.9, 120.4, 113.5, 100.3, 52.6 and 35.2; HRMS-ESI calcd
C22H16BrNO3S[ M +Na] 475.9926, found 475.9945.
Methyl 2-(2-bromo-5-(1-(4-(1,3-dioxoisoindolin-2-yl)butyl)-
2-phenyl-1H-indole-6-carbonyl)-thiophene-3-yl)acetate (10)
To a stirred solution of 9 (45 mg, 0.10 mmol) in anhydrous
CH3CN (5 mL) was added CsF-Celite (125 mg) under N2, followed
by adding N-(4-bromobutyl)-phthalimide (28 mg, 0.10 mmol). The
resulting mixture was refluxed for five hours, cooled to room
temperature, and filtered. The filtrate was evaporated in vacuo.
MPLC purification (Hex:EtOAc/4:1) of the residue gave 10 as
a yellow solid (28 mg, 43%).
1H NMR (400 MHz, CDCl3) d 7.98 (s, 1H), 7.74 (m, 6H), 7.59
(s, 1H), 7.47 (m, 5H), 6.60 (s, 1H), 4.32 (t, 2H, J=7.2 Hz), 3.73 (s,
3H), 3.71 (s, 2H), 3.52 (t, 2H, J=6.8 Hz), 1.72 (m, 2H) and 1.51
(m, 2H);
13C NMR (100 MHz, CDCl3) d 187.3, 170.4, 168.5,
145.2, 144.3, 136.8, 135.6, 134.9, 134.2, 134.1, 132.5, 132.1,
130.7, 129.5, 129.0, 128.8, 123.5, 123.4, 121.5, 120.6, 112.5,
103.1, 52.5, 43.7, 37.3, 35.1, 27.4 and 25.8; HRMS-ESI calcd
C34H27BrN2O5S[ M +Na] 677.0716, found 677.0727.
Methyl 2-(5-(1-(4-(1,3-dioxoisoindolin-2-yl)butyl)-2-pheny-
1H-indole-6-carbonyl-2-(3-hydroxyphenyl)thiophen-3-yl)acetate
(11) To a solution of 3-hydroxyphenylboronic acid (32 mg,
0.23 mmol) in EtOH (1 mL, degassed with N2), was added
a solution of 10 (153 mg, 0.23 mmol) in toluene (5 mL), followed
by adding Pd(PPh3)2Cl2 (16.3 mg, 0.023 mmol) and Na2CO3
(50 mg, 0.46 mmol). The reaction mixture was refluxed for three
hours under N2, and then the solvent was removed in vacuo.
MPLC purification (Hex:EtOAc/2:1) of the residue gave 11 as
a yellow solid (140 mg, 90%).
1H NMR (400 MHz, CDCl3) d 7.98 (s, 1H), 7.70 (m, 2H), 7.64–
7.59 (m, 4H), 7.42–7.33 (m, 6H), 7.24 (t, 1H, J=7.9 Hz), 7.07 (t,
1H, J=2.0 Hz), 6.97 (d, 1H, J=7.6 Hz), 6.85 (dd, 1H, J=2.0,
7.9 Hz), 6.52 (s, 1H), 4.23 (t, 2H, J=7.0 Hz), 3.67 (s, 3H), 3.62 (s,
2H), 3.45 (t, 2H, J=6.8 Hz), 1.67 (m, 2H) and 1.42 (m, 2H);
13C
NMR (100 MHz, CDCl3) d 188.6, 171.9, 168.8, 157.0, 149.2,
145.2, 141.6, 137.8, 136.7, 134.3, 132.6, 132.1, 131.3, 130.5,
130.4, 129.5, 129.0, 128.8, 123.5, 121.7, 121.3, 120.7, 116.5,
112.8, 103.2, 52.6, 43.7, 37.5, 34.6, 27.5 and 25.9; HRMS-ESI
calcd C40H32N2O6S[ M +Na] 691.1873, found 691.1892.
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(3-hydroxyphenyl)-thiophen-3-yl)-N-hydroxyacetamide tri-
fluoroacetic acid salt (2NTFA) To a stirred solution of 11
(50 mg, 0.07 mmol) in THF/MeOH (1 mL each), 1 mL of 50%
aqueous NH2OH was added, followed by adding a catalytic
amount of KCN (CAUTION: KCN is highly toxic and must be
handled with extreme care by trained personnel). The resulting
mixture was stirred overnight at room temperature. After the
solvent was removed in vacuo, the residue was washed with water
(365 mL). HPLC purification of the residue gave 2NTFA as
a yellow powder (32 mg, 65%). HPLC purification condition:
Phenomenex Gemini 5 mm, C18, 4.66250 mm, eluting with
linear gradient of 20% of solution A (1000 mL of H2O and 45 mL
of TFA) to 100% of solution B (100 mL of H2O, 900 mL of
CH3CN, and 45 mL of TFA) over 20 minutes, and flow rate of
1.5 mL/min with a retention time of 12.20 minutes for 2NTFA
(see Figure S2 for chromatograms of 2 before and after the HPLC
purification).
1H NMR (400 MHz, DMSO-d6) d 10.82 (s, 1H), 9.82 (br, 1H),
9.01 (s, 1H), 8.11 (s, 1H), 7.80 (d, 1H, J=2.1 Hz), 7.74 (m, 1H),
7.59–7.50 (m, 6H), 7.30 (m, 1H), 7.04 (d, 1H, J=8.0 Hz), 6.99 (s,
1H), 6.87 (d, 1H, J=8.2 Hz), 6.70 (s, 1H), 4.34 (m, 2H), 3.43 (s,
2H), 2.63 (m, 2H), 1.65 (m, 2H) and 1.31 (m, 2H);
13C NMR
(100 MHz, DMSO-d6) d 187.7, 167.4, 158.5, 148.2, 145.2, 141.5,
138.4, 136.9, 134.3, 133.0, 132.5, 131.7, 131.2, 130.9, 129.8,
129.6, 129.4, 121.2, 121.0, 120.4, 116.7, 116.4, 113.2, 103.3, 43.8,
39.1, 33.1, 27.4 and 25.0; DEPT-135
13C NMR (100 MHz,
CD3OD) d 137.6 (CH), 130.9 (CH), 130.1 (CH), 129.3 (CH),
128.8 (CH), 128.7 (CH), 120.7 (CH), 120.6 (CH), 120.3 (CH),
115.9 (CH), 113.0 (CH), 102.9 (CH), 43.4 (CH2), 39.2 (CH2), 32.3
(CH2), 27.1 (CH2) and 24.7 (CH2); HRMS-ESI calcd
C31H29N3O4S[ M +H] 540.1942, found 540.1934.
Botulinum neurotoxin inhibition assays Assays of pro-
tease activities of BoNTA and botulinum neurotoxin serotype B
(BoNTB) were done at 37uC and contained 0.5 mM substrate,
0.5–1.5 mg/mL recombinant BoNTA/BoNTB endopeptidase,
40 mM HEPES, and 0.05% tween at pH 7.3. BoNTA endo-
peptidase assays also contained 1 mM dithiothreitol, 25 mM
ZnCl2, and 0.5 mg/mL bovine serum albumin, while BoNTB
endopeptidase assays were supplemented with 1 mM dithiothreitol
only. Substrate for BoNTA was a peptide containing residues
187–203 of SNAP-25 [37], while that for BoNTB was residues
60–94 of VAMP [51]. Inhibitors were dissolved in dimethyl
sulfoxide at 10 times the final assay concentration, then diluted
into the assay mixture containing substrate, followed by addition
of endopeptidase (i.e., inhibitor and endopeptidase were not
preincubated). Assay times and endopeptidase concentrations were
adjusted so that less than 10% of the substrate was hydrolyzed.
Assays were stopped by acidification with trifluoroacetic acid and
analyzed by reverse-phase HPLC as described [37]. Inhibition of
BoNTA endopeptidase activity by 1 or 2 was determined in three
independent experiments using eight and nine concentrations of 1
and 2 in each, respectively.
Determination of Ki
app For both inhibitors, Dixon plots
were nonlinear when the entire range of tested concentrations was
included, suggesting a partially competitive inhibition mechanism.
Nonetheless, replots of the linear portion of the data, where
[S],,KM and inhibitor concentrations of 1 and 2 were less than
15.0 mM and 5.4 mM respectively, permitted calculations of Ki
app
values for 1 and 2 using the previously established KM for the
substrate measured in the absence of inhibitor [52] according to
a literature procedure [38,39].
SUPPORTING INFORMATION
Table S1 The AMBER atom types and charges of inhibitors of 1
and 2.
Found at: doi:10.1371/journal.pone.0000761.s001 (0.15 MB
DOC)
Table S2 The AMBER force field parameters of inhibitors of 1
and 2.
Found at: doi:10.1371/journal.pone.0000761.s002 (0.12 MB
DOC)
Figure S1 Definition of atom names of inhibitors of 1 and 2.
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Figure S2 Chromatograms of inhibitor 2 before and after the
HPLC purification.
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